Cite

HARVARD Citation

    Zhu, H. et al. (2018). The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma. Medicine. 97 (25), p. . [Online]. 
  
Back to record